Pityriasis Lichenoides: Diagnosis, Treatment, Outcomes 2025

Introduction

Pityriasis lichenoides (PL) is an uncommon

cutaneous rash

of uncertain aetiology, characterised by a spectrum of inflammatory skin lesions. It encompasses two main forms at opposite ends of the disease spectrum: the

acute form

, known as

pityriasis lichenoides et varioliformis acuta (PLEVA)

, and the

chronic form

,

pityriasis lichenoides chronica (PLC)

. Many patients exhibit overlapping features of both, highlighting the condition’s variable presentation. PL is not contagious and primarily affects the skin, though rare systemic associations have been noted.

The condition typically manifests as recurrent crops of papules that evolve over time, often resolving with post-inflammatory changes such as hyperpigmentation or scarring. While generally benign, severe cases of PLEVA can lead to significant discomfort and cosmetic concerns. Understanding PL is crucial for accurate diagnosis and appropriate management, as it can mimic other dermatoses.

Demographics

Pityriasis lichenoides most commonly affects

children and young adults

, with PLEVA frequently observed in paediatric populations and young individuals under 30 years. It shows a

slight male predominance

, occurring more often in males than females. The condition can arise at any age, but peak incidence is in the first three decades of life. In children, it may present more aggressively as PLEVA, resembling chickenpox-like lesions.

Geographically, no specific predilection is noted, though reports suggest higher recognition in temperate climates where dermatological surveillance is robust. Ethnic variations are minimal, but lesion colour may differ: erythematous on light skin, violaceous or brown on darker skin tones. Incidence is rare, estimated at less than 1% of dermatology referrals, underscoring its uncommon nature.

Causes

The exact

cause of pityriasis lichenoides remains unknown

, but several hypotheses exist based on histopathological and clinical observations. It is postulated as a

hypersensitivity reaction

to foreign antigens, such as infections (bacterial or viral) or medications. The childhood form particularly suggests a reactive process to pathogens, though no specific trigger is consistently identified.

• Infectious triggers: Associations with Epstein-Barr virus, adenovirus, parvovirus, and bacterial toxins have been reported, though causality is unproven.
• Immune dysregulation: PL features a lymphocytic infiltrate, hinting at T-cell mediated immunity, potentially linking to cutaneous T-cell lymphoma in rare malignant transformations.
• Other factors: Vaccinations, drugs, or environmental antigens may precipitate episodes, but evidence is anecdotal.

Importantly, PL is

not hereditary

nor infectious, dispelling common misconceptions. Recent studies explore type 2 inflammation in refractory cases, with elevated IgE and eosinophils in some patients.

Clinical Features

Clinical presentation varies between acute and chronic forms, often overlapping in a single patient.

Pityriasis Lichenoides et Varioliformis Acuta (PLEVA)

**PLEVA presents abruptly** with a rapidly progressive rash of

crops of erythematous papules

(2–10 mm), which evolve into vesicles, pustules, or necrotic centres. Lesions are often

asymptomatic

initially but may become pruritic or painful. They appear on the trunk, proximal limbs, and flexures, resembling chickenpox or varioliform eruptions.

• New lesions: Pink/red papules with central necrosis or ulceration.
• Evolution: Crusting, haemorrhagic scabs heal over 2–4 weeks, often leaving scars or hypopigmentation.
• Skin tone variation: Violaceous-brown on darker skin.

Mucosal involvement (oral, genital) occurs rarely.

Pityriasis Lichenoides Chronica (PLC)

**PLC develops more insidiously** over days to weeks with

flatter, reddish-brown papules

(3–8 mm) featuring adherent scale. Lesions are mildly pruritic and resolve slowly (4–12 weeks) with hyperpigmentation.

• Common sites: Trunk, thighs, flexural areas.
• Chronicity: Waxing/waning for months to years; PLEVA may transition to PLC.

Patients often have polymorphic lesions: acute crops amid chronic patches.

Complications

Most cases are self-limited, but complications include:

• Scarring: Atrophic or hypertrophic scars from necrotic PLEVA lesions, especially in children.
• Hyperpigmentation/hypopigmentation: Post-inflammatory changes, more noticeable in darker skin.
• Secondary infection: Rare, from excoriation of ulcerated lesions.
• Rare severe forms: Febrile ulceronecrotic Mucha-Habermann disease (FUMHD), a PLEVA variant with systemic symptoms, high fever, and potential mortality.
• Malignant potential: Very rare progression to cutaneous T-cell lymphoma.

Diagnosis

Diagnosis is primarily

clinical

, supported by

skin biopsy

. Key histopathological features include:

• Interface dermatitis with vacuolar degeneration.
• Dense lymphocytic infiltrate in dermis/epidermis.
• Exocytosis, parakeratosis, and necrotic keratinocytes (more in PLEVA).

No specific laboratory tests; rule out infections or lymphoma if atypical.

Differential Diagnoses

Condition	Key Distinguishing Features
Chickenpox/VZV	Systemic symptoms, vesicles in crops, positive Tzanck smear.
Pityriasis rosea	Herald patch, Christmas-tree distribution, self-resolves 6–8 weeks.
Guttate psoriasis	Silver scale, Auspitz sign, streptococcal trigger.
Lymphomatoid papulosis	Larger lesions, CD30+ cells on biopsy, lymphoma association.
Drug eruption	History of new medication, eosinophilia.

Treatment

No curative treatment exists; management targets symptoms and hastens resolution. Observation suffices for mild cases.

First-Line Therapies

• Topical glucocorticoids: Potent steroids (e.g., clobetasol) for inflammation/pruritus.
• Topical tacrolimus: Calcineurin inhibitor for steroid-sparing.
• Oral antibiotics: Erythromycin (children) or tetracyclines (adults) for 1–3 months; anti-inflammatory effect.
• Natural sunlight: Helpful adjunct.

Second-Line/Phototherapy

• Narrow-band UVB (NB-UVB): Most effective (47% response); weekly sessions.
• PUVA: Psoralen + UVA for refractory cases, higher side-effect risk.

Advanced Therapies

• Immunosuppressants: Methotrexate, cyclosporine for severe/refractory disease.
• Biologics: Emerging; stapokibart (IL-4/13 inhibitor) showed complete resolution in a case with type 2 inflammation after 12 weeks; dupilumab reported similarly.

Treatment response varies; phototherapy tops efficacy per cohorts. Monitor for side effects, especially in children.

Outcome

**PLEVA** typically resolves in weeks to months, often with scarring.

PLC

persists months to years, waxing/waning; 50–80% remit within 1–3 years. Recurrences common but severity decreases over time. Prognosis excellent; rare progression to malignancy. Patient education on self-limited nature aids coping.

Frequently Asked Questions (FAQs)

Q: Is pityriasis lichenoides contagious?

A: No, PL is not infectious and cannot be spread to others.

Q: Does it go away on its own?

A: Yes, most cases self-resolve within months to years without treatment.

Q: What is the best treatment for children?

A: Erythromycin, topical steroids, and phototherapy are preferred; avoid systemic immunosuppressants initially.

Q: Can it scar?

A: PLEVA often leaves small scars from necrotic lesions; PLC causes pigmentation changes.

Q: Is it related to cancer?

A: Rare association with lymphoma; monitor atypical/persistent cases with biopsy.